Stem cell-based therapy for human diseases
Терапия заболеваний человека на основе стволовых клеток
2022-08-06
SCID: 54.1/8r53p6jq
Discuss with AI
clinical applicationshuman pluripotent stem cellsmesenchymal stem cellsregenerative medicinestem cell-based therapy
Figures from the paper
Abstract (AI)
Recent advancements in stem cell technology open a new door for patients suffering from diseases and disorders that have yet to be treated. Stem cell-based therapy, including human pluripotent stem cells (hPSCs) and multipotent mesenchymal stem cells (MSCs), has recently emerged as a key player in regenerative medicine. hPSCs are defined as self-renewable cell types conferring the ability to differentiate into various cellular phenotypes of the human body, including three germ layers. MSCs are multipotent progenitor cells possessing self-renewal ability (limited in vitro) and differentiation potential into mesenchymal lineages, according to the International Society for Cell and Gene Therapy (ISCT). This review provides an update on recent clinical applications using either hPSCs or MSCs derived from bone marrow (BM), adipose tissue (AT), or the umbilical cord (UC) for the treatment of human diseases, including neurological disorders, pulmonary dysfunctions, metabolic/endocrine-related diseases, reproductive disorders, skin burns, and cardiovascular conditions. Moreover, we discuss our own clinical trial experiences on targeted therapies using MSCs in a clinical setting, and we propose and discuss the MSC tissue origin concept and how MSC origin may contribute to the role of MSCs in downstream applications, with the ultimate objective of facilitating translational research in regenerative medicine into clinical applications. The mechanisms discussed here support the proposed hypothesis that BM-MSCs are potentially good candidates for brain and spinal cord injury treatment, AT-MSCs are potentially good candidates for reproductive disorder treatment and skin regeneration, and UC-MSCs are potentially good candidates for pulmonary disease and acute respiratory distress syndrome treatment.
Key Findings
1
Bone marrow-derived MSCs are proposed as potentially suitable for brain and spinal cord injuries, adipose-derived MSCs for reproductive disorders and skin regeneration, and umbilical-cord-derived MSCs for pulmonary disease and acute respiratory distress syndrome.
2
MSC tissue origin may influence therapeutic function and downstream clinical applications, supporting an origin-guided strategy for translational regenerative medicine.
3
Stem cell-based therapies using human pluripotent stem cells and mesenchymal stem cells are emerging as regenerative treatments for currently difficult-to-treat diseases.
4
The review incorporates the authors’ clinical trial experiences with targeted MSC therapies to support translation into clinical practice.
5
The review summarizes clinical applications of hPSC- and MSC-based therapies across neurological, pulmonary, metabolic/endocrine, reproductive, skin, and cardiovascular disorders.
Research Object
Stem cell-based therapies using human pluripotent stem cells and mesenchymal stem cells derived from bone marrow, adipose tissue, or umbilical cord for treating human diseases
Research Subject
Clinical applications, therapeutic suitability, and tissue-origin-dependent mechanisms of hPSCs and MSCs in regenerative treatment of neurological, pulmonary, metabolic/endocrine, reproductive, skin, and cardiovascular diseases
Publication Details
Publication Date
2022-08-06
Journal
Publisher
ISSN
Cited by
1081
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest